ClinicalTrials.gg
RecruitingNCT07197827Updated Nov 12, 2026

A Study of YL242 in Subjects With Advanced Solid Tumors

A Phase 1/2 interventional study of YL242 and YL242; Pembrolizumab in Advanced Solid Tumor, sponsored by MediLink Therapeutics (Suzhou) Co., Ltd.. Recruiting at 15 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know · 8 judgments

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Updated Nov 12, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
424
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, open-label study to evaluate the safety and tolerability of YL242 monotherapy and combination in participants with advanced solid malignant tumors.

02

Conditions studied

  • Advanced Solid Tumor

Browse trials for

Keywords

  • Oncology
  • VEGF
  • Antibody drug conjugate
  • Developmental Phase I/II
03

In context

Neoplasms

10,837 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's planned enrollment of 424 is above the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

MediLink Therapeutics (Suzhou) Co., Ltd. is the lead sponsor of 23 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years.
  • performance status (ECOG PS) of 0 or 1
  • Adequate organ and bone marrow function
  • Tumor type:

Part 1-3: Advanced/unresectable or solid malignant tumor; Have received at least one prior line of systemic anti-tumor therapy

Part 4: locally advanced or metastatic non-sq NSCLC without AGA and HCC; Have not received any systemic anti-tumor therapy;

Part 5: mCRC, have received at least one (5a) or one (5b) prior line of systemic anti-tumor therapy

Part 6: advanced or metastatic -negative G/GEJ; have received at least one (6a) or one (6b) prior line of systemic anti-tumor therapy

Exclusion criteria

Exclusion Criteria:

  • Be intolerant to prior treatment with a topoisomerase I inhibitor or an ADC that consists of a topoisomerase I inhibitor
  • Uncontrolled or cardiovascular and cerebrovascular diseases
  • Clinically significant concomitant pulmonary disease
  • A history of or carcinomatous meningitis
  • Any illness, medical condition, organ system dysfunction, or social situation, including but not limited to mental illness or substance/alcohol abuse, deemed by the investigator to be likely to interfere with a patient's ability to sign , adversely affect the patient's ability to cooperate and participate in the study, or compromise the interpretation of study results
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
424 participants (estimated)

Study arms

  • Experimental
    Part 1 and Part 2: Mono Dose Escalation & Expansion

    Participants receive YL242 administered via intravenous (IV) solution per protocol defined dose level and frequency.

    Drug: YL242

  • Experimental
    Part 3 and 4: Combination Dose Escalation & Expansion

    Participants receive YL242 at protocol defined dose level, in combination with Pembrolizumab (200 mg), administered via intravenous (IV) solution at protocol defined dose level and frequency.

    Drug: YL242; Pembrolizumab

  • Experimental
    Part 5: Combination Dose Optimization and Expansion

    Participants receive YL242, 5-FU and LV, administered via intravenous (IV) solution.

    Drug: YL242; 5-FU; LV

  • Experimental
    Part 6: Combination Dose Optimization and Expansion

    Participants receive YL242, pembrolizumab and 5-FU, administered via intravenous (IV) solution at protocol defined frequency.

    Drug: YL242; Pembrolizumab; 5-FU

Interventions

  • DrugYL242

    The YL242 drug product is provided as a lyophilized powder containing 200 mg of YL242 in a glass vial. The initial dose of YL242 will be infused IV into each patient for 90±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL242 will be infused IV into each patient for 60±10 minutes.

  • DrugYL242; Pembrolizumab

    Drug page: PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The YL242 drug product is provided as a lyophilized powder containing 200 mg of YL242 in a glass vial. The initial dose of YL242 will be infused IV into each patient for 90±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL242 will be infused IV into each patient for 60±10 minutes. Pembrolizumab will be administered subsequent to YL242.

  • DrugYL242; 5-FU; LV

    Drug page: FluorouracilStudies of FluorouracilFluorouracil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The YL242 drug product is provided as a lyophilized powder containing 200 mg of YL242 in a glass vial. The initial dose of YL242 will be infused IV into each patient for 90±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL242 will be infused IV into each patient for 60±10 minutes. LV and 5-FU will be sequentially administered following YL242.

  • DrugYL242; Pembrolizumab; 5-FU

    Drug pages: PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · FluorouracilStudies of FluorouracilFluorouracil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The YL242 drug product is provided as a lyophilized powder containing 200 mg of YL242 in a glass vial. YL242 will be administered via Intravenous (IV) Infusion. Pembrolizumab and 5-FU will be administered in sequence after YL242.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) in Participants With Advanced Solid Malignant Tumors (Part 2, and 4-6)

    Objective response rate (ORR) was defined as the proportion of participants who achieve either complete response \[CR\] or partial response \[PR\] per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

    Time frame: Approximately within 36 months

  2. Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs)

    AEs will be collected systematically from signing of the informed consent form (ICF) through 42 days after last dose.

    Time frame: Baseline up to 42 days post last patients last dose, approximately within 36 months

Secondary outcomes

  1. Area Under the Serum Concentration Time Curve (AUC) of YL242

    Time frame: Approximately within 36 months

  2. Maximum Plasma Concentration (Cmax) of YL242

    Time frame: Approximately within 36 months

  3. Time to Maximum Plasma Concentration (Tmax) of YL242

    Time frame: Approximately within 36 months

  4. Incidence of anti-YL242 antibody

    Time frame: Approximately within 36 months

  5. Terminal Elimination Half-life (t1/2) of Serum YL242

    Time frame: Approximately within 36 months

  6. Disease Control Rate (DCR)

    Disease control rate (DCR) was calculated as the proportion of participants demonstrating complete response (CR), partial response (PR), or stable disease.

    Time frame: Approximately within 36 months

07

Study locations

14 of 15 sites recruiting
  • US-201
    New Haven, Connecticut 06519, United States
    Recruiting
    • study coordinator · Contact
  • US-202
    Sarasota, Florida 34232, United States
    Recruiting
    • study coordinator · Contact
  • US-204
    Boston, Massachusetts 02215, United States
    Recruiting
    • study coordinator · Contact
  • US-206
    Grand Rapids, Michigan 49546, United States
    Recruiting
    • study coordinator · Contact
  • US-205
    Nashville, Tennessee 37203, United States
    Recruiting
    • study coordinator · Contact
  • US-203
    Houston, Texas 77030, United States
    Not yet recruiting
    • study coordinator · Contact
  • US-207
    San Antonio, Texas 78229, United States
    Recruiting
    • study coordinator · Contact
  • AUS-101
    Liverpool, New South Wales 2170, Australia
    Recruiting
    • study coordinator · Contact
  • AUS-102
    Darlinghurst, Victoria 2010, Australia
    Recruiting
    • study coordinator · Contact
  • AUS-104
    Fitzroy, Victoria 3065, Australia
    Recruiting
    • study coordinator · Contact
  • AUS-103
    Heidelberg, Victoria 3084, Australia
    Recruiting
    • study coordinator · Contact
  • AUS-105
    Nedlands, Western Australia 6009, Australia
    Recruiting
    • study coordinator · Contact
  • CN-303
    Harbin, Heilongjiang 150081, China
    Recruiting
    • study coordinator · Contact
  • CN-301
    Shanghai, Shanghai Municipality 200030, China
    Recruiting
    • study coordinator · Contact
  • CN-302
    Hangzhou, Zhejiang 310022, China
    Recruiting
    • study coordinator · Contact
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2028, 36 months after the start.

Of 197 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 36 months is below that.

Counting every sponsor, half of 299 studies reached it within 61 months; a quarter within 40 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2025
First posted
Sep 29, 2025
StartActual
Sep 22, 2025
Primary completionEst.
Sep 2028
CompletionEst.
Nov 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites changed recruiting status (7 now recruiting)
Show 7 sites
  • US-201 · New Haven, United StatesNot yet recruiting→Recruiting
  • US-204 · Boston, United StatesNot yet recruiting→Recruiting
  • US-207 · San Antonio, United StatesNot yet recruiting→Recruiting
  • AUS-101 · Liverpool, AustraliaNot yet recruiting→Recruiting
  • AUS-104 · Fitzroy, AustraliaNot yet recruiting→Recruiting
  • AUS-103 · Heidelberg, AustraliaNot yet recruiting→Recruiting
  • AUS-105 · Nedlands, AustraliaNot yet recruiting→Recruiting
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    7 sites changed recruiting status (7 now recruiting)
    Show 7 sites
    • US-201 · New Haven, United StatesNot yet recruiting→Recruiting
    • US-204 · Boston, United StatesNot yet recruiting→Recruiting
    • US-207 · San Antonio, United StatesNot yet recruiting→Recruiting
    • AUS-101 · Liverpool, AustraliaNot yet recruiting→Recruiting
    • AUS-104 · Fitzroy, AustraliaNot yet recruiting→Recruiting
    • AUS-103 · Heidelberg, AustraliaNot yet recruiting→Recruiting
    • AUS-105 · Nedlands, AustraliaNot yet recruiting→Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07197827
Responsible party
Sponsor
First posted
Sep 29, 2025
Start date
Sep 22, 2025
Primary completion
Sep 2028 (estimated)
Completion
Nov 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Medilink Study Team
Contact
clinicaltrials@medilinkthera.com
+86 0512-62858368

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pembrolizumab · Fluorouracil

Start the discussion